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Abstract: Background: Current treatment approaches for pediatric ependymoma differ between North American and 
European studies. Post-surgical adjuvant irradiation is used in children aged <36 months in North America, whilst 
European approaches use chemotherapy to avoid or defer radiotherapy until three years of age, in order to avoid late 
neurocognitive toxicity. To establish evidence for the effects of cranial radiotherapy in children aged <36 months with 
ependymoma on neurocognitive outcomes, we conducted a systematic literature review assessing methodological 
approaches for measuring neurocognitive outcome. Methods: Eight databases were selected to perform an advanced 
search, retrieval and systematic review of papers describing neurocognitive outcome in children diagnosed with 
ependymoma who received cranial radiotherapy at <36 months. Results: Limitations of published data permitted 
descriptive analysis only. Considerable variation in reporting survival rates, techniques and timing of psychometric 
testing and the results of neurocognitive outcomes was identified. Conclusions: The review identified significant 
inconsistencies of neurocognitive testing, particularly literacy skills, developmental time points for testing and methods of 
data reporting. The role of the cerebellum for cognitive development, especially reading, has been inadequately 
evaluated in published studies. Recommendations are made to improve assessment methods, and time points for 
testing, so that reports do not fail to identify children who acquire deficits as they mature through childhood and 
adolescence. We conclude that claims that radiation treatment for ependymoma administered aged <36 months is 
associated with limited neurocognitive consequences, are not supported by the literature. 
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INTRODUCTION 
Ependymoma arising at less than 16 years of age 
account for 10% of brain tumours in the age group, 
>50% present in the pre-school age group (<5yrs) and 
<80% presenting by eight years of age [1,2]. Ninety 
percent of pediatric ependymomas are intracranial in 
origin with two-thirds arising from the lining of the fourth 
ventricle in the posterior fossa [3]. The young age bias 
coupled with the complexities of achieving complete 
resection of tumour involving the brain stem and 
cerebellum have contributed to poor outcomes 
because of incomplete resections and restricted use of 
radiotherapy linked to risks of neurotoxicity affecting 
cognitive development and other long-term clinical 
sequelae [4-6].  
Concerns regarding the long-term cognitive and 
learning impairments of irradiating immature brain 
structures, particularly supratentorial regions and its  
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impact on developing cognitive functions, have led 
some centres to employ strategies to delay or avoid the 
delivery of radiotherapy by using chemotherapy first. 
Understandably, much research in neurooncology 
focuses on survival rates as primary outcome 
measures, whilst lower priorities have historically been 
allocated to neurocognitive and learning outcome 
measures as drivers for change in treatments [7]. An 
exception to this [8] is the reporting from North America 
of the use of highly conformal radiotherapy as the 
primary adjuvant therapy in children aged <36 months 
with ependymoma [9]. This approach contrasts with 
many European centres which are continuing to use 
radiotherapy-deferral strategies with adjuvant 
chemotherapy. 
This difference in clinical practice highlights the 
importance of considering the neurocognitive conse-
quences for radiotherapy given to the very immature 
brain, particularly the posterior fossa [10]. Although the 
cerebellum has been thought to be devoted almost 
entirely to motor control [11], namely skilled voluntary 
movements, muscle tone, posture and gait, a growing 
body of empirical data implicates the developing 
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cerebellum in diverse higher cognitive functions [12], 
especially acquisition of literacy skills [13-15]. 
Furthermore, neuroendocrine sequelae and second 
cancers after radiotherapy, adversely influence quality 
of survival [16-18]. In order to investigate the impact of 
different treatment regimes [19] a systematic literature 
review of publications describing the neurocognitive 
outcomes of children with ependymoma who received 
radiotherapy at <36 months of age was conducted. 
MATERIALS AND METHODS 
Search Strategy 
An advanced search was performed in AMED, 
BIOSIS Previews, CAB Abstracts, EMBASE, Ovid 
MEDLINE, PsycINFO, CINAHL and Cochrane Library 
for articles published in English from database 
commencement to date. All databases were searched 
using the terms: ((ependymoma*) OR (post* adj2 
fossa*) OR (post*-fossa*)) AND ((child*) OR (p?ediat*)) 
AND ((radiotherapy*) OR (radiat* adj2 therap*) OR 
(irradiat*) OR (stereotactic adj2 surger*) OR (gamma 
adj2 knife) OR (IMRT) OR (chemotherap* adj2 wafer*) 
OR (proton adj2 therap*) OR (photon adj2 therap*) OR 
(brachytherap*)) AND ((neurocognit*) OR (neuro adj2 
cognit*) OR (psychometric*) OR (neurometric*) OR 
(learning*) OR (educat*) OR (neuropsych*) OR 
(psycholog*) OR (cognit*)).  
Selection Criteria 
Three members of the review team read the 
retrieved papers independently and identified data for 
the agreed categories presented in Tables 1, 2 and 3. 
Inclusion was dependent on two criteria: 
1. The paper reported participants receiving 
irradiation at three years of age or under for the 
treatment of ependymoma. 
2. The paper reported participants’ neurocognitive 
or psychometric outcomes. 
Level of evidence was determined independently by 
three investigators using indicators as defined by the 
Centre for Evidence Based Medicine [20] (Table 1). 
Statistical Analysis 
The retrieved data did not permit meta-analysis or 
use of a vote count procedure because of inconsis-
tencies across studies in their use of comparable 
neuropsychological and psychometric assessments or 
lack of detailed reporting of children with significantly 
impaired performance. Consequently, a descriptive 
analysis was performed. Data were presented using 
the following categories: number of patients with 
ependymoma; age at irradiation; grade and site; non-
radiological treatments received; residual disease 
stated; presence of hydrocephalus; radiation dose; 
survival rate; psychometry used; described impairment; 
global outcomes and level of evidence [20]. 
Table 1: Oxford Centre for Evidence-Based Medicine 
Levels of Evidence Summary 
Levels of 
Evidence 
Requirement 
1a Systematic review (with homogeneity) of RCTs 
1b 
Individual RCT (with narrow confidence 
interval) 
1c All or none case series 
2a 
Systematic review (with homogeneity) of cohort 
studies 
2b Individual cohort study 
2c ‘Outcomes’ research 
3a 
Systematic review (with homogeneity) of case 
control studies 
3b Individual case-control study 
4 Case series 
5 Expert opinion without critical appraisal 
RESULTS 
In total, 291 papers were retrieved. Figure 1 
illustrates the retrieval process which was completed in 
accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) 
statement [21]. 
After removing duplicates, the remaining 141 
papers were evaluated to determine inclusion. Nine 
studies met the inclusion criteria (Table 2). A further 
five studies did not provide specific information for age 
at the time of irradiation but stated that patients were 
less than five years (Table 3). An additional 11 studies 
indicated the inclusion of patients with ependymoma 
but age could not be determined from data provided 
(Supplementary Table).  
Retrieved Studies of Children <36 Months 
Diagnosed with Ependymoma 
Nine references were retrieved from 1990-2011 
(Table 1). Of the retrieved references, 88.8% (8/9 
papers) met level 2c [20] for quality of evidence with 
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[25] at 3b [20]. Two pairs of papers described the same 
patients [8, 22, 24, 27]. The total number of patients 
involved in all nine studies was 184. Of these, 35.9% 
(66/184) were irradiated at <36 months (0.67 [8 
months]-2 years). The first study [7] contained two 
protocols for irradiation where the highest dose was 
70.4Gy prior to 2001 and then 59.4Gy from 2001 
onwards. Mean and standard deviation for all ages 
were not calculated as three papers [8, 26, 27] did not 
specify a mean but stated patients were irradiated at 
<36 months. Of the 35.9% irradiated at <36 months, 
80.3% (53/66) had an infratentorial location with 13.6% 
(9/66) having supratentorial. The remaining four 
patients (6.5%) irradiated at <36 months from one 
paper [23] were not identified as either infra- or 
supratentorial. 
Of the 66 patients, all received neurosurgery. For 
13.6% (9/66) the level of resection was unspecified, 
86.4% (57/66) had Gross-Total Resection (GTR), 6.1% 
(4/66) had Near-Total Resection (NTR) and 9.1% 
(6/66) had Subtotal Resection (STR). Of all patients, 
25.8% (17/66) received chemotherapy in addition to 
irradiation. A maximum of seven patients may have 
received chemotherapy in addition to irradiation but this 
is not described [7, 25]. Where reported, hydro-
cephalus was present in 74.2% (49/66) of patients 
irradiated at <36 months. 
Radiation and Chemotherapy Treatment Received 
Radiation dosage was reported in 77.7% (7/9) of the 
studies, ranging from 40-704Gy. For [7] in the 1994-
2001 period, patients with complete tumour excision 
received hyperfractionated RT (1.1. Gy twice a day) to 
the tumour bed plus 1-2 cm margins up to a total dose 
of 70.4 Gy. Where residual tumour was identified, four 
chemotherapy (CT) doses with vincristine, etoposide 
 
 
Figure 1: Retrieval Algorithm in accordance with PRISMA Guidelines. 
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and cyclophosphamide (VEC) +/- second look surgery 
followed by the described radiotherapy (RT) protocol 
were given. After 2001, patients with complete 
resection and Grade II revised histology had CRT with 
conventional fractionation of 1.8 Gy/d. Patients with 
complete excision and Grade III revised histology 
received four VEC courses after RT. With residual 
tumour of any grade VEC was given before RT to 
facilitate second look surgery. In [22, 24] no detailed 
RT protocol is described but presence and complexity 
of hydrocephalus with required treatment is given [22]. 
For [23] adjuvant treatment was planned to start within 
four weeks of surgery and followed two different 
treatment protocols. In regimen I (1994-2003) four 
blocks of vincristine (1.5 mg/m
2
) plus high-dose 
methotrexate 5g/m
2
 with cyclophosphamide 1.5 g/m
2
 
alternating with cisplatin 90 mg/m
2
 plus VP16 450 
mg/m
2
 for year one. Regimen II included VEC: VCR 
1.5mg/m
2
 plus VP16 300mg/m
2
 and CTX 3g/m
2
 for six 
months. CT was discontinued following disease 
progression. RT was planned only for patients with 
residual tumour after CT or progression of tumour while 
receiving CT. RT doses and schedules varied 
according to the used protocol: hyperfractionated RT 
(1.1 Gy twice a day) administered to the tumour bed 
with a 1-2 cm margin (margin reduction was adopted 
during that time according to physicians’ experience 
and literature), up to 70.4 Gy for children treated before 
2001, or conformal RT using conventional fractionation 
of 1.8 Gy a day up to a total of 54-59 Gy after 2001. 
Post operative and pre-irradiation MRI defined the 
residual disease and possibly collapsed post-surgical 
tumour bed. The planning target volume was 0.5 cm 
larger than the clinical target volume in all directions. 
No reduction of fields or radiation boost was planned in 
case of residual tumour. No detailed information 
regarding RT is provided in [25]. For [26] total dose 
ranged from 50-62 Gy, administered in five weekly 
sessions of 1.8 Gy per day. For patients early in the 
series, radiographic simulation images with hand-
drawn tailored shielding based upon physician 
knowledge of anatomical structures and tumour 
characteristics were used. For those treated later, 3D 
high definition CT-based representation of dose-
distribution superimposed with posterior fossa 
structures and tumour contour were available. The 
GTV for the primary site boost included the post-
operative tumour bed. The CTV included in the GTV 
with an anatomically confined margin of 2 cms in the 
adjacent brain whereas the PTV expanded the CTV 
with a geometric margin of 1 cm. Multiple beam 
arrangements were used. Their initial approach 
induced full dose to the entire posterior fossa including 
occipital and posterior temporal areas. Only the 
pituitary area located at the anterior margin was kept to 
an ‘acceptable’ level. The later approach permitted 
reduced maximal dose to most structures outside the 
posterior fossa. Papers [8, 27] present the same 
patients. The GTV contained the tumor bed, residual 
tumor, or both. The CTV contained the GTV with an 
added margin of 1 cm, which was included so that 
subclinical microscopic disease beyond the GTV could 
be treated. The CTV was anatomically confined; that is, 
it was limited by normal tissue structures through which 
tumor extension was unlikely. The planning target 
volume included the CTV surrounded by an additional 
margin of 3 to 5mm, expanded in three dimensions to 
account for uncertainty in patient positioning and image 
registration. Conventional fractionation (1.8 Gy per day) 
was used to treat all patients, and the prescribed dose 
was 59.4 Gy. Exceptions included children younger 
than 18 months and three children older than 18 
months who received 54.0 Gy after gross-total 
resection. For [28] minimal data regarding RT is 
provided. 
Mortality and Neurocognitive Morbidity 
Typically, survival rates were not stated. When they 
were included (33.3%; 3/9) the calculation had been 
completed for all patients (of any age at irradiation or 
any tumour type in mixed studies) and ranged from 
20% at five years [28] and 74.7% at three years [8]. A 
total of 13 different psychometric tests were used 
(excluding editions of the same test e.g. WISC III and 
WISC IV were classed as one test, three of which were 
proxy measures - CBCL, PedsQL and VABS). Five 
studies used Wechsler ability measures (WPPSI, 
WPPSI-R, WISC-III, WISC-IV, WAIS-R and WAIS-III to 
obtain IQ [7,8,22,26,27]. Three studies [23,25,28] 
reported IQ scores and/or scholastic performance with 
no indication as to how this was obtained. One study 
stated that patients who were not irradiated did not 
demonstrate better outcomes than those who were 
[23]. Another indicated that radiation dosimetry was the 
most clinically significant determinant of IQ outcome 
[27] with a further [28] agreeing that radiation before 36 
months was ‘very hazardous’ for mental sequelae. One 
study suggested that radiotherapy was unlikely to be 
the only factor contributing to poor neurocognitive 
outcome in young children [26]. A further paper [7] 
suggested that tumour location and pre-/perioperative 
damage seemed to affect cognitive outcome more than 
age at RT.  
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DISCUSSION 
This systematic literature review has identified only 
limited data from published studies regarding morbidity 
and mortality of post surgical irradiation. There is 
significant scope to develop a better evidence base 
and improve neurocognitive assay.  
Sixty-six children under 36 months received 
radiotherapy with 80% (53/66) of these children 
receiving infratentorial radiotherapy and 14% (9/66) 
supratentorial radiotherapy. For the remaining children, 
anatomical site was not specified. One child was 
irradiated (infratentorial) at <12 months. Of 14 papers 
reaching minimum quality standards, nine papers 
indicated radiotherapy for childhood ependymoma 
leads to lower IQ scores or poorer overall cognitive 
outcome [22, 27, 28, 31, 33, 35, 37, 42, 44] compared 
to norms. One of these studies [28] suggested that 
young age at CRT is a further risk factor with Di Pinto 
et al. [31] stating that young age at irradiation leads to 
smaller rates of increase in learning over time and 
Kieffer-Renaux et al. [37] noting that IQ continues to 
decline more than four years post diagnosis. Conklin et 
al. [32] identify that young age at CRT affects reading 
ability with Pulsifer et al. [44] finding significant decline 
in processing speed and visual-spatial organisation in 
childhood ependymoma survivors. In contrast, six of 
the retrieved papers stated CRT does not predict 
poorer cognitive outcomes [7,23,29,30,36,41]. Further 
to this, Merchant and colleagues [8] state that being 
less than 36 months old at time of radiotherapy may 
lead to lower IQ but that this is a product of the tumour 
itself and following CRT, cognition may improve over 
time. It is important to note that improvements may well 
occur but as a consequence of the normal 
neurodevelopmental process. What remains unclear is 
whether the rate of new learning and skill acquisition 
post CRT is commensurate with typical cognitive 
trajectories. Poggi et al. [39] found that young age (0-
6yrs) at radiotherapy leads to lower cognitive 
impairment. Young age and CRT may not be the only 
factors leading to a reported decline in cognitive 
function. For example, cognitive deficits or low IQ may 
be predicted by radiation dosimetry [27], tumour 
location [7,42]; pre- or perioperative brain damage [7] 
or presence of lacunae [38]. The presence and 
management of hydrocephalus are also implicated as 
factors effecting cognitive outcome [29]; however, 
Davis et al. [22] did not replicate this finding with no 
consistent effect of hydrocephalus on outcome 
demonstrated. Where IQs are reported, large inter- 
 
individual differences [22] were present with no 
definitive explanation provided accounting for this 
variability. 
Twenty-five papers were found to include childhood 
ependymoma patients who had received radiotherapy 
as treatment. In comparison to the wealth of studies 
available for mortality rates, there is a paucity of work 
describing cognitive morbidity for irradiated survivors of 
childhood ependymoma. Of the few studies that 
investigated this and are consequently included in this 
review, a majority were rated at 2b for quality of 
evidence [20]. In all but one of the twenty-five studies 
reviewed, the number of ependymoma patients could 
be identified clearly. However, determining patient age 
at diagnosis, treatment or follow-up was not 
straightforward. Scrutiny of retrieved papers led to 
three categories of data emerging. Nine papers (Table 
2) stated explicitly that patients were irradiated for 
ependymoma at <36 months. Five references (Table 3) 
included patients who received radiotherapy for an 
ependymoma at <60 months. Therefore, some of these 
patients may have been <36 months but this 
information could not be ascertained. Finally, eleven 
papers (Supplementary Table) presented children who 
were treated with radiotherapy for ependymoma but 
age was not specified. Data were of variable quality. 
Where ependymoma patients were clearly identifiable 
their numbers ranged from 1-88. Those that included 
ependymoma patients only led to more accessible 
data. In papers where more than one brain tumour type 
was discussed, data regarding irradiation outcomes for 
ependymoma were more difficult to access. 
Methodological limitations are present in the 
retrieved papers. There is inconsistency for data 
reporting ensuring comparisons and more standard 
forms of statistical scrutiny cannot presently be 
performed. The use of psychometry was an inclusion 
criterion for papers in this review and, therefore, all 
papers discussed make reference to some form of 
neurocognitive assessment and outcome. However, 
there are inconsistencies across the retrieved papers 
for the measures used and the way in which obtained 
results were reported. Across all studies, 16 different 
measures were used to explore neurocognitive func-
tioning in differing combinations. Some commonality 
occurs with 696% (18/25) of papers using a Wechsler 
test to establish IQ. In three studies IQ is stated but no 
information is given regarding how this was obtained. 
Four papers discuss vague descriptions of scholastic 
outcomes.  
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Comparisons cannot be made across all papers, as 
there is a lack of sufficient data delineation and strati-
fication. Some papers (e.g. [22]) compare the out-
comes of irradiated ependymoma survivors according 
to neurological results such as ‘presence/absence’ of 
hydrocephalus. They also include the numbers of 
patients who received radiotherapy but do not compare 
results according to treatment received, possibly due to 
small sample size. Hydrocephalus has been identified 
as a potential risk factor for cognitive decline following 
a brain tumour such as ependymoma [29] but its 
presence or absence was only reported in 68% (17/25) 
of the studies. Other reasons for poor outcomes are 
included within studies variably. For example, radiation 
dosimetry is well reported (22/25 studies) as is tumour 
location in 19/25. The main issue with this information 
is that it cannot be specifically identified for 
ependymoma patients and, therefore, conclusions 
cannot be drawn. Publishing of individual data via 
supplementary tables may help to improve analysis to 
ensure accurate neurocognitive prognosis for this 
group. The benefits of this approach have been 
demonstrated with other neurocognitively impaired 
paediatric groups e.g. [45,46]. 
Given the likely role of the cerebellum in cognitive 
development and the demonstrated variability in the 
neurocognitive outcomes for this group, it is not 
presently possible to be confident that these children 
will be unaffected in the long term. Current evidence 
indicates the cerebellum is involved in the construction 
and organisation of higher cognitive functions and 
social behaviours [47] typically associated with the 
prefrontal cortex. This reflects the integrated network of 
neural inputs into the cerebellum from all levels of the 
CNS, including spinal, vestibular and cerebral 
pathways. Damage to the cerebellar hemispheres has 
been shown to be associated with intellectual changes, 
with damage to the vermis associated with behavioural 
changes [13]. Reciprocal projections between the 
cerebellum and cerebral cortex provide a plausible 
neuroanatomical basis for a cerebellar role in cognition 
[47]. While damage to either cerebellar hemisphere 
produce ipsilateral motor deficits, projections from the 
cerebellum to the cerebral cortex are contralateral. 
Consistent with this structural organisation, evidence 
indicates lateralized cerebellar lesions produce 
cognitive deficits similar to those observed following 
lesions of the contralateral cerebral hemisphere [48]. It 
is hypothesized that this may be caused by disruption 
of the metabolic activity to cerebello-cortical pathways 
[49,50]. Therefore, verbal functions and/or literacy defi-
cits, in right-handed individuals, have been associated 
with right cerebellar damage and visuospatial deficits 
with left cerebellar damage [13]. Because of the 
increasing role attributed to the cerebellum in higher 
cognitive functions [15] and acquisition of literacy 
[12,14], cerebellar dysfunction secondary to the tumour 
and its treatment(s) is implicated as having a major 
detrimental effect on intellectual, cognitive, learning 
and functional outcomes [51].  
Although the retrieved papers testify to the 
importance of assessing neurocognitive outcomes, it is 
critical to note that no clear neurodevelopmental model 
is ever presented to account for the findings. This is 
concerning as its omission limits a complete and long-
term understanding of cognitive development and its 
impairment or indeed resilience for this group of 
children. The timing of acquired damage, the period of 
cognitive development and brain maturation all provide 
the potential for demonstrated adverse ‘downstream 
effects’ on yet to be acquired skills, such as literacy 
and later cognition [52]. The recognition of a primary 
damage leading to later manifesting secondary impair-
ments ensures the need for long-term prospective 
surveillance of neurocognitive outcomes. For example, 
as modest associations exist between developmental 
tests and later IQ [53], it is inappropriate to draw 
definitive conclusions regarding patients’ likely 
cognitive abilities and learning outcomes in later life 
from measures used in early childhood. In addition, the 
maximum length of follow-up for ependymoma patients 
was 60 months post treatment [8]. Thus, if the patient 
was 36 months when receiving radiotherapy their 
maximum age at follow-up would be eight years. This 
period of follow up has created the claim [3] that 
learning in these children remain unaffected. 
‘Mechanical’ literacy skills i.e. reading accuracy and 
spelling, continue to develop beyond eight years of age 
[54] with the comprehension of read materials 
becoming increasingly important. Some papers (e.g. 
[8]) provide the mean scores for the reading accuracy 
and spelling components of literacy. Reading 
comprehension remains unassessed. A child learns to 
read, then reads to learn. If acquisition of literacy is 
impaired then all that flows from this will be affected 
similarly. Impaired literacy acquisition across childhood 
can adversely affect IQ in the long-term [55]. From 
Table 2, only 4/9 studies examine literacy in different 
and incomplete ways. Given the evidence for cerebellar 
involvement in the acquisition of literacy, more detailed 
prospective assay of reading is now required. Cognition 
and learning continue to unfold beyond eight years of 
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age and outcomes beyond this remain unknown. In 
addition, there is evidence that children who are initially 
assessed as without difficulties may develop significant 
later, more global, impairments to cognitive functioning 
due to the phenomenon of ‘growing into deficit’ [56]. 
With improved follow-up and consistent neurocognitive 
assay, treating and research communities may be 
better able to substantiate the claim for an absence of 
adverse neurocognitive sequelae for irradiation at <36 
months. While a complete absence of late neurocog-
nitive effects may not be a realistic aim, the aim to 
address methodological variation and inconsistent 
capture of neurocognitive outcome is. 
Sample size varies and data collection is retrospec-
tive or prospective. The technique of RT used; timing of 
RT; role of multiple surgery and presence of cerebellar 
mutism are described variably. In [8] patients were 
treated with post-surgical RT for initial management. 
For [23] most received RT as part of a salvage strategy 
including repeat surgery. Multiple resection and 
anticipated and non-anticipated post-neurosurgical 
complications may restrict clarity of conclusion further. 
Given the variability of data presentation and differing 
opinions regarding the role of RT in neurocognitive 
sequelae it is recommended that data capture should 
be standardised. To better establish the longer-term 
risk for this group, data collection for the following are 
suggested: presence of cerebellar mutism, tracheos-
tomy rates; vascular events; number of days in PICU; 
number of surgeries performed; presence of residual 
disease; premorbid difficulties; ability and literacy 
outcomes, using Wechsler tests. 
Claims [8,19] for the absence of long-term 
neurocognitive impairment in childhood ependymoma 
(3 years of age) require further evaluation as retrieved 
evidence questions this view. From retrieved evidence, 
considerable variability in neurocognitive outcome is 
demonstrated for children who received radiotherapy 
for ependymoma at this age. The retrieved papers 
raise the question of the type of data needed by the 
treating and research community to fully understand 
the long-term neurocognitive consequences of 
ependymoma and their treatments. Without this, the 
actual morbidity and the full costs of long term 
neurodisability, unemployment and underemployment 
will never be known. This paper only reviews the 
reported neurocognitive sequelae of photon radiother-
apy for young ependymoma patients. As proton 
radiotherapy is increasingly being used it is important 
to address consistency of methodology and data 
reporting. Although at present it may not be possible to 
achieve consensus for international clinical practice, it 
is crucial to establish a common agreement for study 
design; neurocognitive development, learning and its 
measurement; consistency and delineation of data 
capture and reporting, and duration of follow-up, to 
allow systematic comparisons across studies to be 
made. The International Society for Paediatric 
Oncology (SIOP) is currently working towards this.  
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